Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement




Mar
25
Today In Oncology
FDA Approves Relacorilant With Nab-Paclitaxel for Several Platinum-Resistant Gynecologic Cancers
Awareness of Alcohol-Cancer Link Holds Steady Despite Omission in New US Dietary Guidelines
Myelofibrosis Treatment Landscape Is Poised for Change
AI Model Classifies Challenging Thymic Epithelial Tumors
Study Finds Inferior Survival Among Black Patients With AML, Independent of Cytogenetic Risk
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo